Lytix Biopharma

[PaddyO]

Her spørs det vel veldig på videre finansiering. Men med PCIB godt i minne………

[TekBot]

Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization

Oslo, Norway, August 28, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, today announced its results for the second quarter and first half of 2025.

The first half of the year has been a period of steady clinical progress and preparation. Lytix advanced across clinical, regulatory and organizational priorities, building a stronger foundation for the decisive period ahead.
…

Vis børsmeldingen

• Over the past years, we have validated Lytix technology across several cancer types and indications with strong results in a variety of patient populations. Our technology has demonstrated proof-of-concept across various skin cancers, highlighting a significant and urgent need for new treatment alternatives. The gap in today’s treatment options is positioning Lytix and our drug candidates at the forefront for cancer treatment of tomorrow, said Dr. Øystein Rekdal, CEO of Lytix Biopharma.

At the center of this progress is Ruxotemitide (formerly LTX-315). The program has matured with the assignment of its international nonproprietary name (INN), a successful End-of-Phase II FDA meeting for basal cell carcinoma through partner Verrica, and completion of patient treatment in the ATLAS-IT-05 trial in advanced melanoma. In parallel, enrollment is progressing in the NeoLIPA study in early-stage melanoma, with interim results expected in November 2025.

These clinical steps are complemented by a strengthened leadership team and board, reflecting Lytix’s transition from clinical exploration toward late-stage development, partnering, and future commercialization.

• We are moving step by step toward patients. With the completion of our advanced melanoma trial and progress in early-stage melanoma, Ruxotemitide is transitioning into earlier disease settings where therapeutic potential is greater. Alongside our partner Verrica’s preparations for Phase III in basal cell carcinoma, the coming months will be a milestone-rich period for Lytix, said Rekdal.

H1 2025 highlights and developments
• Licensing partner Verrica Pharmaceuticals had a successful end-of-phase II FDA meeting for Ruxotemitide in basal cell carcinoma; alignment on advancing to Phase III
• Verrica plans to present a comprehensive update on the clinical development plan with Ruxotemitide in BCC program, including genomic and immune response data, at a scientific conference later in 2025
• Completion of patient treatment in the ATLAS-IT-05 Phase II trial in advanced melanoma, with disease control in ~40% of patients and systemic immune responses observed
• Ongoing enrollment in the NeoLIPA study in early-stage melanoma (around one third of patients treated); interim results expected November 11, 2025 at the Nordic Melanoma Meeting
• Strengthened board and executive team to support commercial readiness and partnerships
• Cash and short-term investments totaled NOK 100.3 million as of June 30, 2025
• ATLAS-IT-05 accruals reduced by NOK 10.2 million due to lower trial drug costs (non-cash adjustment)

With data updates from Verrica, interim NeoLIPA results, and Phase III preparations in basal cell carcinoma, Lytix enters the second half of 2025 with multiple upcoming catalysts and a clear path toward broader clinical impact and future commercialization.

Webcast details:
The results will be presented in a webcast with CEO Øystein Rekdal and CFO Gjest Breistein today.

Date: Thursday, August 28th, 2025
Time: 10:00 AM CEST

Questions may be submitted in advance to: post@lytixbiopharma.com

The presentation and Q&A session will be conducted in English. You can view the live event by registering here: https://channel.royalcast.com/landingpage/hegnarmedia/20250828_5/

A recording will be available after the event at: Financial Reports - Lytix Biopharma

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, Ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[Hotdog]

Ruxotemitide - The drug earlier known as ltx 315.

[Dreamliner]

Ca en tredje del av pasientene i Neo-Lipa studien er behandlet. Det betyr sannsynligvis 9 pasienter. I mai var 8 pasienter behandlet. Hvorfor kan de ikke si antallet i meldingen? Er det fordi det går tregt at de ikke vil si nøyaktig antall?

[drdr]

Lytix Biopharma Q1’25 interview with CEO Øystein Rekdal

[Alex]

Kan jo ta med analyse (extended update) av rapport også

Lytix Biopharma Q2 2025: Extended Update

sitat:
The last patient was treated in Q2 in the phase II study in metastatic melanoma, ATLAS-IT-5.
Lytix will present interim data at the Nordic Melanoma Meeting on 11 November 2025 from
NeoLIPA, the study in Neoadjuvant patients, a non-metastatic setting. This can be a major
trigger. The primary endpoint is pathological complete response. Historical controls are around
20-27%, so above 40% would be a success.

Kan bli moro tradingmessig og for de langsiktige i november altså.

[the1nonly]

Optimismen fra presentasjonen smitter omvendt på kursen. Verrica bruker sykt lang tid på å finne en partner som er interessert ta dette videre. Er det tvil om om det blir noe fase 3 som slår ut på kursen?

[Hotdog]

Kombinasjon av få innrullerte pasienter i neolipa, tvil om fase 3 verrica og at ting generelt tar veldig lang tid med både Lytix og verrica (guidingen holdes ikke). Foreløpig er ingenting fundamentalt endret slik jeg ser det. At kursen faller på lav omsetning er bare en liten dump i veien.

[TekBot]

Lytix Biopharma AS: Grant of share options to management and key personnel

Oslo, Norway – 1 September 2025 – Lytix Biopharma AS (the “Company”) announces that the Board of Directors has approved the grant of 4,910,484 share options under the Company’s long-term incentive program.

The grants cover replacement of expired options earlier this year and allocations to strengthen the incentive structure for new and existing members of the management team. The program is designed to attract, retain, and motivate highly qualified talent to drive the Company’s clinical, commercial, and strategic objectives.
…

Vis børsmeldingen

“Equity incentives are a key tool for aligning management with shareholder interests, particularly in the biotech sector where long development timelines and the inherent risk of joining a biotech require a strong focus on sustainable value creation. This program ensures that our experienced leadership team remains fully committed to delivering on our mission and advancing our clinical pipeline to commercial success”, says Øystein Rekdal, CEO of Lytix Biopharma.

Key terms of the grants
• The total number of share options granted is 4,910,484.00.
• Each option gives the right to acquire one share in the Company at an exercise price of NOK 7.98, which equals the closing share price of the Company on Euronext Growth Oslo, the day prior to grant of the options.
• For selected long-tenured executives, a portion of the share options will vest immediately (2,389,170 share options)
• The remaining 2,521,314 share options will vest over a four-year period, 25% vesting 12 months after grant (630,329 share options), and the remaining 75% (1,890,985 share options) vesting in equal monthly installments (1/36) over the following 36 months.
• All options expire five years after the date of grant.

The following primary insiders have been granted options:
• Øystein Rekdal, CEO – 1,627,860 options
• Baldur Sveinbjørnsson, CSO – 923,930 options
• Gjest Breistein, CFO – 615,620 options
• Mette Husbyn, CTO – 341,310 options

Please refer to the forms appended hereto for the disclosure of option grants to primary insiders of the Company.

For further information, please contact:
Gjest Breistein, CFO
Email: gjest.breistein@lytixbiopharma.com

This information is subject to disclosure under section 5-12 of the Norwegian Securities Trading Act and article 19 of the Market Abuse Regulation.

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

Kilde

[drdr]

Det skal skje i dag kl 15:30

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.

H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025
Event details:
Date: Monday, September 8, 2025
Time: 9:30 am ET
Location: New York, New York

Participants may access a live webcast of the event by clicking the link here.

https://verrica.com/press_release/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference/

[Amaru]

Noen som får inn sendingen???